Energy and nutrient homeostasis is maintained through a complex regulatory network formed by signaling and transcriptional components that control metabolic genes. In this regulatory network, metabolic flexibility in skeletal muscle is defined as the ability to undergo a nutrient switch of fuel substrate utilization between glucose and fatty acids. Clinically, the metabolic syndrome that include an array of risk factors such insulin resistance, obesity and dyslipidemia among others is associated with a loss of metabolic flexibility. Moreover, it is though that it is this lack of metabolic flexibility that correlates with an incomplete mitochondrial oxidation of fatty acids and increased accumulation of intramyocellular lipids, a putative cause of insulin resistance. We have identified an important component of the low nutrient/fasting switch from glucose to fatty acid oxidation that involves the SIRT1 deacetylase enzyme that targeting and activating the transcriptional coactivator PGC- 1a promotes this nutrient switch. Mimicking fasting metabolic response, active and deacetylated PGC-1a increases expression of genes encoding for regulatory proteins and enzymes linked to mitochondrial fatty acid oxidation. Interestingly, this pathway is altered in skeletal muscle of mice fed with high fat diet in which PGC- 1a is highly acetylated and correlates with a loss of metabolic flexibility and insulin resistance. Although activation of SIRT1 and PGC-1a are key regulators of this process, how low nutrient signals control SIRT1 enzymatic activity and how mechanistically deacetylated PGC-1a is a hyperactive protein is unknown. The major goal of this proposal is to identify the mechanisms by which fasting and low nutrient signals to SIRT1 enzymatic activity to induce PGC-1a deacetylation in skeletal muscle and to investigate their metabolic functionality in in-vivo mouse models. We have three aims:
Aim 1 is to perform molecular and functional analysis of how fasting/low glucose controls SIRT1 deacetylase enzymatic activity in in-vitro as well in-vivo conditions.
Aim 2 is to carry out molecular and functional analysis of PGC-1a acetylation and identify new proteins that account for the hyperactivity of deacetylated PGC-1.
Aim 3 will determine the effects of fasting/PKA activation on glucose and lipid metabolism through generation of skeletal muscle transgenic mice expressing SIRT1 and PGC-1a mutant alleles in different dietary conditions. This investigation will allow us to identify the molecular mechanisms by which fasting and PKA activation in skeletal muscle controls glucose and lipid metabolism. Since dysregulation of these processes that involves a loss of metabolic flexibility is a major component of the metabolic syndrome including obesity and diabetes, our studies on the regulation of SIRT1 deacetylase activities and PGC-1a acetylation might translate into potential therapeutic interventions.

Public Health Relevance

Dysregulation of the SIRT1/PGC-1a function in skeletal muscle leads to loss of metabolic flexibility and altered mitochondrial oxidation. Since this is a hallmark of metabolic diseases such as obesity and type 2 diabetes, studies in this grant proposal might translate into potential therapies for these diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK069966-09
Application #
8502467
Study Section
Special Emphasis Panel (ZRG1-EMNR-B (02))
Program Officer
Margolis, Ronald N
Project Start
2004-12-01
Project End
2015-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
9
Fiscal Year
2013
Total Cost
$541,632
Indirect Cost
$216,455
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Sharabi, Kfir; Lin, Hua; Tavares, Clint D J et al. (2017) Selective Chemical Inhibition of PGC-1? Gluconeogenic Activity Ameliorates Type 2 Diabetes. Cell 169:148-160.e15
Rines, Amy K; Sharabi, Kfir; Tavares, Clint D J et al. (2016) Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. Nat Rev Drug Discov 15:786-804
Sharabi, Kfir; Tavares, Clint D J; Rines, Amy K et al. (2015) Molecular pathophysiology of hepatic glucose production. Mol Aspects Med 46:21-33
Kraus, Daniel; Yang, Qin; Kong, Dong et al. (2014) Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature 508:258-62
Lee, Yoonjin; Dominy, John E; Choi, Yoon Jong et al. (2014) Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression. Nature 510:547-51
Dominy, John E; Puigserver, Pere (2013) Mitochondrial biogenesis through activation of nuclear signaling proteins. Cold Spring Harb Perspect Biol 5:
Hall, Jessica A; Dominy, John E; Lee, Yoonjin et al. (2013) The sirtuin family's role in aging and age-associated pathologies. J Clin Invest 123:973-9
Dominy, John; Puigserver, Pere; Cantó, Carles (2013) In vivo measurement of the acetylation state of sirtuin substrates as a proxy for sirtuin activity. Methods Mol Biol 1077:217-37
Lim, Ji-Hong; Gerhart-Hines, Zachary; Dominy, John E et al. (2013) Oleic acid stimulates complete oxidation of fatty acids through protein kinase A-dependent activation of SIRT1-PGC1? complex. J Biol Chem 288:7117-26
Dominy Jr, John E; Lee, Yoonjin; Jedrychowski, Mark P et al. (2012) The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis. Mol Cell 48:900-13

Showing the most recent 10 out of 25 publications